Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK and Theravance have announced the submission of a regulatory application for Anoro Ellipta (UMEC/VI) (62.5/25mcg and 125/25mcg doses) in Japan.
Subscribe to our email newsletter
UMEC/VI combines a long-acting muscarinic antagonist (LAMA) GSK573719 or umeclidinium bromide and a long-acting beta2 agonist (LABA) vilanterol (VI), administered using the Ellipta inhaler.
The investigational once-daily LAMA/LABA combination medicine UMEC/VI is developed for patients with chronic obstructive pulmonary disease (COPD).
A new drug application has been submitted as a maintenance bronchodilator treatment to relieve symptoms of obstructive airway disorder coupled with COPD.